ArticleJournal of the Endocrine Society2021
Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists.
Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Quality of life in primary aldosteronism, medical vs surgical treatment: a systematic review and meta-analysis.Journal of endocrinological investigation · 2026Pooled it
- Effects of perirenal fat accumulation on cardiometabolic and renal functions and mineralocorticoid receptor activation in primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Antihypertensive effects and changes in extracellular water content by mineralocorticoid receptor antagonists in patients with primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- Short-term longitudinal clinical, biochemical, and quality of life outcomes of medical or surgical therapy in unilateral primary aldosteronism.Frontiers in endocrinology · 2025Article
- Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Recent progress in the diagnosis and treatment of primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Update on Hypertension Research in 2021.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Improvement in quality of life and psychological symptoms after treatment for primary aldosteronism: Asian Cohort Study.Endocrine connections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAlthough primary aldosteronism (PA) reduces quality of life (QOL), there have been no reports on whether treatment with a mineralocorticoid receptor antagonist (MRA) improves QOL in Japanese PA patients.
objectiveUsing the 36-Item Short-Form Health Survey (SF-36), we compared the QOL of PA patients before and after treatment and evaluated whether the effectiveness of MRAs differs by sex and serum potassium level.
methodsIn 50 patients diagnosed with PA (with or without hypokalemia) and treated with an MRA, the SF-36 scores, blood pressure, and clinical features were assessed before, and 3 and 6 months after treatment. Separate analyses were also conducted for males and females.
resultsThe normative mean SF-36 score of the healthy subjects was 50. The pretreatment Role-Physical (RP) (46.7 ± 1.8,
conclusionMRAs improved the QOL of Japanese PA patients, but female PA patients may be more resistant to MRAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.